Li HL, Lip GYH, Feng Q, et al. - Researchers analyzed clinical trials of patients with heart failure (HF), diabetes mellitus (DM), or chronic kidney disease (CKD), to examine the link between sodium-glucose cotransporter 2 inhibitors (SGLT2i) treatment and arrhythmia outcomes. They identified randomized controlled trials that randomized patients with DM, CKD, or HF to SGLT2i or placebo, by exploring MEDLINE, EMBASE, and ClinicalTrials.gov. A lower risk of atrial fibrillation (AF), embolic stroke, AF/atrial flutter (AFL), and ventricular tachycardia was observed in relation to SGLT2i, while the risk attenuations in AFL and cardiac arrest did not reach statistical significance. Overall, a decrease in the risk of cardiac arrhythmias was documented in relation to the use of SGLT2i. This work offers further evidence for recommending SGLT2i employment in cases with DM, CKD, and HF.